Kyntra Bio (KYNB) Competitors $6.99 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.96 -0.04 (-0.50%) As of 05/22/2026 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYNB vs. CGTX, UPXI, NRXP, QTTB, and BMEAShould you buy Kyntra Bio stock or one of its competitors? MarketBeat compares Kyntra Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyntra Bio include Cognition Therapeutics (CGTX), Upexi (UPXI), NRx Pharmaceuticals (NRXP), Q32 Bio (QTTB), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. KYNB vs. CGTXKYNB vs. UPXIKYNB vs. NRXPKYNB vs. QTTBKYNB vs. BMEAHow does Kyntra Bio compare to Cognition Therapeutics?Kyntra Bio (NASDAQ:KYNB) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership. Do analysts prefer KYNB or CGTX? Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 164.55%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Kyntra Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is KYNB or CGTX more profitable? Kyntra Bio has a net margin of 2,199.13% compared to Cognition Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyntra Bio2,199.13% N/A -36.71% Cognition Therapeutics N/A -72.68%-53.07% Do insiders & institutionals hold more shares of KYNB or CGTX? 72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 2.0% of Kyntra Bio shares are held by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to KYNB or CGTX? In the previous week, Cognition Therapeutics had 3 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Cognition Therapeutics and 0 mentions for Kyntra Bio. Cognition Therapeutics' average media sentiment score of 0.50 beat Kyntra Bio's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kyntra Bio Neutral Cognition Therapeutics Neutral Which has higher earnings and valuation, KYNB or CGTX? Kyntra Bio has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyntra Bio$6.44M4.40$183.45M$40.460.17Cognition TherapeuticsN/AN/A-$23.49M-$0.24N/A Which has more risk and volatility, KYNB or CGTX? Kyntra Bio has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. SummaryKyntra Bio beats Cognition Therapeutics on 9 of the 16 factors compared between the two stocks.How does Kyntra Bio compare to Upexi?Upexi (NASDAQ:UPXI) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment. Which has higher valuation & earnings, UPXI or KYNB? Kyntra Bio has lower revenue, but higher earnings than Upexi. Upexi is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpexi$15.81M5.95-$13.68M-$0.62N/AKyntra Bio$6.44M4.40$183.45M$40.460.17 Do institutionals & insiders believe in UPXI or KYNB? 5.7% of Upexi shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 9.0% of Upexi shares are held by company insiders. Comparatively, 2.0% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is UPXI or KYNB more profitable? Kyntra Bio has a net margin of 2,199.13% compared to Upexi's net margin of -874.00%. Kyntra Bio's return on equity of 0.00% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Upexi-874.00% -66.70% -19.56% Kyntra Bio 2,199.13%N/A -36.71% Does the media favor UPXI or KYNB? In the previous week, Upexi had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 1 mentions for Upexi and 0 mentions for Kyntra Bio. Upexi's average media sentiment score of 0.59 beat Kyntra Bio's score of 0.00 indicating that Upexi is being referred to more favorably in the media. Company Overall Sentiment Upexi Positive Kyntra Bio Neutral Which has more risk & volatility, UPXI or KYNB? Upexi has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Do analysts prefer UPXI or KYNB? Upexi currently has a consensus price target of $8.33, indicating a potential upside of 521.89%. Given Upexi's stronger consensus rating and higher possible upside, research analysts clearly believe Upexi is more favorable than Kyntra Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 SummaryUpexi beats Kyntra Bio on 9 of the 16 factors compared between the two stocks.How does Kyntra Bio compare to NRx Pharmaceuticals?NRx Pharmaceuticals (NASDAQ:NRXP) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Do analysts rate NRXP or KYNB? NRx Pharmaceuticals presently has a consensus target price of $38.25, suggesting a potential upside of 1,087.89%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Kyntra Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Which has more risk & volatility, NRXP or KYNB? NRx Pharmaceuticals has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Which has preferable valuation & earnings, NRXP or KYNB? Kyntra Bio has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx Pharmaceuticals$1.23M94.85-$28.62M-$1.09N/AKyntra Bio$6.44M4.40$183.45M$40.460.17 Is NRXP or KYNB more profitable? Kyntra Bio has a net margin of 2,199.13% compared to NRx Pharmaceuticals' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -202.92% Kyntra Bio 2,199.13%N/A -36.71% Do institutionals & insiders have more ownership in NRXP or KYNB? 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer NRXP or KYNB? In the previous week, NRx Pharmaceuticals had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 1 mentions for NRx Pharmaceuticals and 0 mentions for Kyntra Bio. NRx Pharmaceuticals' average media sentiment score of 0.67 beat Kyntra Bio's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment NRx Pharmaceuticals Positive Kyntra Bio Neutral SummaryNRx Pharmaceuticals and Kyntra Bio tied by winning 8 of the 16 factors compared between the two stocks.How does Kyntra Bio compare to Q32 Bio?Q32 Bio (NASDAQ:QTTB) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Is QTTB or KYNB more profitable? Kyntra Bio has a net margin of 2,199.13% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 149.23% beat Kyntra Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A 149.23% 34.50% Kyntra Bio 2,199.13%N/A -36.71% Does the media prefer QTTB or KYNB? In the previous week, Q32 Bio had 5 more articles in the media than Kyntra Bio. MarketBeat recorded 5 mentions for Q32 Bio and 0 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.00 beat Q32 Bio's score of -0.14 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Overall Sentiment Q32 Bio Neutral Kyntra Bio Neutral Which has higher earnings and valuation, QTTB or KYNB? Kyntra Bio has lower revenue, but higher earnings than Q32 Bio. Kyntra Bio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio$53.74M1.83$29.82M$2.662.18Kyntra Bio$6.44M4.40$183.45M$40.460.17 Do insiders & institutionals have more ownership in QTTB or KYNB? 31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by insiders. Comparatively, 2.0% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer QTTB or KYNB? Q32 Bio presently has a consensus target price of $13.50, indicating a potential upside of 132.76%. Given Q32 Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Q32 Bio is more favorable than Kyntra Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Which has more volatility and risk, QTTB or KYNB? Q32 Bio has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. SummaryQ32 Bio beats Kyntra Bio on 9 of the 17 factors compared between the two stocks.How does Kyntra Bio compare to Biomea Fusion?Kyntra Bio (NASDAQ:KYNB) and Biomea Fusion (NASDAQ:BMEA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Do analysts prefer KYNB or BMEA? Biomea Fusion has a consensus price target of $8.29, indicating a potential upside of 483.50%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Kyntra Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has preferable earnings & valuation, KYNB or BMEA? Kyntra Bio has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyntra Bio$6.44M4.40$183.45M$40.460.17Biomea FusionN/AN/A-$61.80M-$0.68N/A Does the media refer more to KYNB or BMEA? In the previous week, Biomea Fusion had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 1 mentions for Biomea Fusion and 0 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.00 equaled Biomea Fusion'saverage media sentiment score. Company Overall Sentiment Kyntra Bio Neutral Biomea Fusion Neutral Is KYNB or BMEA more profitable? Kyntra Bio has a net margin of 2,199.13% compared to Biomea Fusion's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Kyntra Bio2,199.13% N/A -36.71% Biomea Fusion N/A -265.37%-103.96% Which has more volatility and risk, KYNB or BMEA? Kyntra Bio has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market. Do institutionals and insiders believe in KYNB or BMEA? 72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Comparatively, 18.4% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryKyntra Bio beats Biomea Fusion on 8 of the 14 factors compared between the two stocks. Get Kyntra Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KYNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYNB vs. The Competition ExportMetricKyntra BioPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$28.30M$927.43M$4.26B$12.34BDividend YieldN/A4.84%5.93%5.28%P/E Ratio0.171.4621.9025.65Price / Sales4.40119.63180.5586.28Price / CashN/A20.0755.6856.67Price / Book-0.927.5934.857.14Net Income$183.45M-$3.64M$112.32M$335.98M7 Day Performance2.34%1.93%2.55%3.56%1 Month Performance-2.10%76.78%3.54%2.54%1 Year PerformanceN/A126.62%15.79%35.05% Kyntra Bio Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYNBKyntra Bio0.464 of 5 stars$6.99flatN/AN/A$28.30M$6.44M0.17570Gap DownCGTXCognition Therapeutics3.4094 of 5 stars$1.14-5.0%$3.33+192.4%+324.4%$107.40MN/AN/A20UPXIUpexi1.7968 of 5 stars$1.45-4.6%$8.33+474.7%-87.5%$106.80M$15.81MN/A130Gap UpNRXPNRx Pharmaceuticals3.0291 of 5 stars$3.28+2.2%$38.25+1,066.2%+22.9%$106.15M$1.23MN/A2QTTBQ32 Bio3.5256 of 5 stars$6.30+0.8%$13.00+106.3%+258.0%$105.98M$53.74M3.6139Analyst Forecast Related Companies and Tools Related Companies CGTX Competitors UPXI Competitors NRXP Competitors QTTB Competitors BMEA Competitors LONA Competitors ONCY Competitors ALDX Competitors CUE Competitors FRMM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYNB) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyntra Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyntra Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
